Registry for Malignant Peripheral Nerve Sheath Tumors

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This observational study aims to create a worldwide registry to collect and analyze clinical data related to malignant peripheral nerve sheath tumors (MPNST) associated with neurofibromatosis type 1 (NF1). It will utilize a retrospective approach to gather standardized information on histology, treatment, and molecular data from various expert centers globally. The registry will also include biospecimens and genetic data to facilitate comprehensive analyses of these tumors. By identifying patterns and trends in the data, the study seeks to enhance understanding and management of MPNSTs.

Why it matters

Who can join: the full rules

Inclusion Criteria and Exclusion Criteria:

-Any patient diagnosed with an MPNST is eligible for enrollment to this registry provided s/he consents to participate (or consent form his/her parent or legal guardian or legally authorized representative is obtained).

Where it's running

• Johns Hopkins
  Baltimore, Maryland, United States Recruiting
• Washington University School of Medicine
  St Louis, Missouri, United States Recruiting
• Mount Sinai
  Toronto, Ontario, Canada Recruiting
• Nagoya University Hospital
  Nagoya, Showa Ward, Japan Recruiting
• Moffitt Cancer Center
  Tampa, Florida, United States Completed
• National Institutes of Health (NIH)
  Bethesda, Maryland, United States Not yet recruiting

Study contacts

• Principal investigator: Angela Hirbe, M.D., Ph.D. — Washington University School of Medicine
• Study coordinator: Angela Hirbe, M.D., Ph.D.
• Email: hirbea@wustl.edu
• Phone: (314) 362-8965

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• Safety and preliminary activity of BMS-986504 in unresectable MPNST

  A new medicine called BMS-986504 is being tested to see if it is safe and may help people with unresectable malignant peripheral nerve sheath tumors, especially those whose tumors lack MTAP.

  Recruiting Phase 1/2 Case Comprehensive Cancer Center · Cleveland, Ohio · NCT07549022

• MASCT-I plus doxorubicin and ifosfamide as first-line treatment for advanced soft tissue sarcoma

  This trial will test whether adding MASCT-I to standard chemotherapy (doxorubicin and ifosfamide) helps adults with advanced soft tissue sarcoma respond better or live longer.

  Recruiting Phase 2 HRYZ Biotech Co. · Guangzhou · NCT06277154

• Testing selinexor for treating Wilms tumors and other solid tumors

  This study is testing if selinexor can help children with certain hard-to-treat tumors, like Wilms tumors, feel better and improve their health.

  Recruiting at 16 sites Phase 2 Memorial Sloan Kettering Cancer Center · Los Angeles, California and 15 other locations · NCT05985161

• Testing MRTX1719 for solid tumors with MTAP deletion

  This study is testing a new drug called MRTX1719 to see if it can help people with advanced solid tumors that have a specific gene deletion.

  Recruiting at 22 sites Phase 1 Bristol-Myers Squibb · Phoenix, Arizona and 24 other locations · NCT05245500

• B7-H3 CAR T-cell therapy for pediatric solid tumors

  This study is testing a new type of immune therapy using specially modified T cells to see if it can help children with tough-to-treat solid tumors.

  Recruiting Phase 1 St. Jude Children's Research Hospital · Memphis, Tennessee · NCT04897321

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.